Improved levothyroxine pharmacokinetics after bariatric surgery.

Area of Science:

• Endocrinology
• Pharmacokinetics
• Bariatric Surgery

Background:

• Levothyroxine (LT4) absorption is influenced by various factors.
• Bariatric surgery is a common treatment for severe obesity.
• Understanding LT4 absorption post-bariatric surgery is crucial for managing thyroid hormone levels.

Purpose of the Study:

• To evaluate the impact of bariatric surgery on levothyroxine (LT4) pharmacokinetic parameters.
• To identify the gastrointestinal absorption sites of LT4 in severely obese patients before and after bariatric procedures.

Main Methods:

• A study involving 32 severely obese nonhypothyroid patients undergoing sleeve gastrectomy, Roux-en-Y gastric bypass, or biliopancreatic diversion with long limbs.
• Blood samples were collected pre- and post-surgery after oral administration of LT4 (600 μg) to estimate pharmacokinetic parameters like AUC, Cmax, and Tmax.

Main Results:

• Sleeve gastrectomy (SG) showed increased mean AUC post-surgery (p<0.01).
• Biliopancreatic diversion with long limbs (BPD-LL) demonstrated significantly higher mean AUC and Cmax post-surgery (p<0.001).
• Roux-en-Y gastric bypass (RYGBP) showed no significant changes in LT4 pharmacokinetic parameters.

Conclusions:

• Levothyroxine (LT4) absorption is enhanced after sleeve gastrectomy (SG) and biliopancreatic diversion with long limbs (BPD-LL) bariatric procedures.
• The findings suggest that the stomach, duodenum, and upper jejunum are not primary sites for LT4 absorption.
• Absorption of LT4 likely occurs in the lower gastrointestinal tract, distal to the bypassed or removed segments.